A scaled back version of a 2017 bill that sought to cap drug costs will instead follow a route successful in California, requiring drug manufacturers to explain big price increases
Rep. Rob Nosse, D-Portland, has found bipartisan, bicameral support for legislation to improve the price transparency for pharmaceuticals, giving momentum to passage that eluded advocates last year.
Summary: On May 24, 2017, the Type 1 Diabetes Defense Foundation filed two new lawsuits in federal court with class-action law firm Keller Rohrback, L.L.P., seeking disclosure of manufacturers’ net realized prices on blood glucose test strips and emergency glucagon kits, both used in diabetes treatment. Following on T1DF’s insulin pricing lawsuit filed March 17, 2017 (Boss, et al. v. CVS, et al.), T1DF now joins with individual plaintiffs in test strip claim Prescott, et al. v. CVS, et al. and glucagon claim Bewley, et al. v. CVS, et al., expanding its consumer rights campaign against the unconscionable pricing of essential pharmaceuticals. These lawsuits are consistent with T1DF’s opposition to “rebates” and other hidden pricing practices that raise list prices for diabetes drugs and supplies while disincentivizing innovation, promoting clinical inertia, undermining therapeutic adherence and encouraging discrimination against people with diabetes.
June 15, 2017 - Eugene, OR. Glucagon rescue kits provide an emergency injection of glucagon, a hormone that raises blood sugar, in case of life-threatening severe low blood sugar.